---
figid: PMC6089847__gr2
figtitle: Pathways of T-cell inactivation and mechanisms of monoclonal antibodies
organisms:
- NA
pmcid: PMC6089847
filename: gr2.jpg
figlink: /pmc/articles/PMC6089847/figure/f0010/
number: F2
caption: Pathways of T-cell inactivation and mechanisms of monoclonal antibodies.
  Pembrolizumab, Atezolizumab, and Nivolumab shut off the PD-1/PD-L1 T-cell inactivation
  pathway, one of many ligand-receptor pathways that contribute to T-Cell inactivation
  against tumor cells.
papertitle: 'Personalized medicine in non-small cell lung cancer: a review from a
  pharmacogenomics perspective.'
reftext: Wenxiao Jiang, et al. Acta Pharm Sin B. 2018 Jul;8(4):530-538.
year: '2018'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.5581372
figid_alias: PMC6089847__F2
figtype: Figure
organisms_ner:
- Homo sapiens
redirect_from: /figures/PMC6089847__F2
ndex: 36ea4408-df33-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6089847__gr2.html
  '@type': Dataset
  description: Pathways of T-cell inactivation and mechanisms of monoclonal antibodies.
    Pembrolizumab, Atezolizumab, and Nivolumab shut off the PD-1/PD-L1 T-cell inactivation
    pathway, one of many ligand-receptor pathways that contribute to T-Cell inactivation
    against tumor cells.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - CD274
  - CD80
  - PDCD1LG2
  - PVR
  - CD86
  - PDCD1
  - RPL17
  - RPL17-C18orf32
  - PAF1
  - CTLA4
  - TIGIT
  - HAVCR2
---
